hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06334822 id: HFT-2024-01 briefTitle: Randomised Controlled Trial for Assessing the Effectiveness of an Inclusive Heart Failure Monitoring and TRACKing Solution in the UK. acronym: HF-TRACK overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-04-30 date: 2025-04-30 date: 2024-03-28 date: 2024-03-28 name: Heartfelt Technologies class: INDUSTRY briefSummary: The objective of our research is to evaluate the effectiveness of an innovative medical device designed to measure foot and lower leg sizes in detecting early indications of deteriorating heart failure. This health condition frequently causes leg swelling and breathing difficulties due to fluid accumulation. Early detection of these symptoms is vital for effective management, potentially preventing the need for hospitalization.
Fluid retention in the lower legs and lungs, manifesting as swollen ankles and shortness of breath, is a common sign of progressing heart failure. Often, a slight increase in body weight is the first warning of fluid accumulation, occurring before noticeable swelling or breathing issues arise. Early identification of these fluid accumulation signs is critical for timely intervention, which can avert the necessity for hospital admittance. Patients are usually encouraged to monitor their weight, check for swelling in the ankles, observe their breathing, and consult with their healthcare provider or heart failure specialist at the first sign of these symptoms. In many cases, patients can report these symptoms in time for their healthcare team to adjust their treatment accordingly. Diuretics, or water pills, are often prescribed to help eliminate excess fluid, effectively preventing hospital admissions when used promptly.
The Heartfelt device may provide a useful solution for individuals who find it challenging to consistently monitor these indicators and their weight. It is designed to detect early warning signs seamlessly without imposing additional tasks on the patient's daily routine. The device, intended to complement rather than replace self-monitoring practices, is user-friendly and operates by scanning the feet for any size changes, positioned conveniently by the bedroom floor. This capability allows healthcare professionals to make informed decisions swiftly about patient care, potentially adjusting treatments to avoid further health complications. The device captures images of the feet only, ensuring privacy.
This study aims to ascertain the device's practical effectiveness in real-world scenarios, aiming to collect precise data to confirm its potential benefits for patients facing heart failure challenges. conditions: Heart Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This 6-month study involves up to 210 patients using the Heartfelt device at home. It is a crossover trial with a 21-day break between two 69-day periods to prevent overlap effects. Patients will either receive standard care or standard care plus Heartfelt alerts. The Heartfelt group is further divided into three 23-day sub-studies to test different alert systems.
Another 60 patients will have monthly measurements taken at the pharmacy without being part of the main randomisation. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Only outcomes assessors will be blinded. whoMasked: OUTCOMES_ASSESSOR count: 270 type: ESTIMATED name: Heartfelt Device installed name: Standard care name: Questionnaires name: Heartfelt Device in pharmacy name: Heartfelt device alerting system measure: All-Cause Mortality Rate. measure: Heart Failure Hospitalisation Incidence. measure: Device-Related Complication Rate. measure: Comparison of Data Availability (number of days with data in a month): Heartfelt Device vs. Existing Remote Monitoring Devices measure: Hospital Admission Duration measure: Cause of Hospitalization measure: Date of Changes in HF Medication Post-Discharge measure: Changes in dosage of HF Medication Post-Discharge measure: Cause of Death measure: Date of Death measure: Loss of Independence measure: Hospitalisation Admission Route measure: Scheduling of Care Events measure: Setting of Care Events measure: Timestamp of Health Alerts Generated by the Heartfelt Device measure: Frequency of Health Alerts Generated by the Heartfelt Device measure: Foot volume measure: Peripheral oedema grading measure: Weight sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dr R Raut & Partnership (General Practice) city: Hull state: East Riding Of Yorkshire zip: HU7 5DD country: United Kingdom name: Rajeev Raut, MD role: CONTACT phone: +441482 835880 email: HF-TRACK@hftech.org name: Rajeev Raut, MD role: PRINCIPAL_INVESTIGATOR lat: 53.7446 lon: -0.33525 hasResults: False
nctId: NCT06334809 id: 028FPO22 briefTitle: INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations acronym: INSIDE overallStatus: RECRUITING date: 2023-03-09 date: 2026-12-31 date: 2027-12-31 date: 2024-03-28 date: 2024-03-28 name: Fondazione del Piemonte per l'Oncologia class: OTHER briefSummary: 400 patients will be enrolled and divided into 3 cohorts: Cohort A: patients with high risk localized prostate cancer (PC) defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE or SVI at mpMRI;
Cohort C: patients with metastatic castration resistant prostate cancer (mCRPC) progressing on a standard treatment. conditions: Prostate Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 400 type: ESTIMATED measure: Number, type and frequency of DDR and MMR germline/somatic alterations measure: Changes in PSA levels in the 3 cohorts measure: Number of patient-derived preclinical models sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo status: RECRUITING city: Candiolo state: Turin zip: 10060 country: Italy name: Pasquale Rescigno, MD role: CONTACT email: pasquale.rescigno@ircc.it name: Ilaria Buondonno, PhD role: CONTACT phone: +390119933393 email: ilaria.buondonno@ircc.it lat: 44.95858 lon: 7.59812 facility: AOU San Luigi Gonzaga status: RECRUITING city: Orbassano state: Turin zip: 10060 country: Italy name: Francesco Porpiglia, MD role: CONTACT lat: 45.00547 lon: 7.53813 hasResults: False
nctId: NCT06334796 id: 10476 briefTitle: Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology acronym: AIDEN overallStatus: COMPLETED date: 2023-10-01 date: 2024-01-01 date: 2024-01-01 date: 2024-03-28 date: 2024-03-28 name: Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia class: OTHER name: Entelai briefSummary: This study examines the use of an AI-powered virtual assistant for quickly identifying and handling neurological emergencies, particularly in places with limited medical resources. The research aimed to check if this AI tool is safe and accurate enough to move on to more advanced testing stages. In a first-of-its-kind trial, the virtual assistant was tested with patients having urgent neurological issues. Neurologists first reviewed the AI's recommendations using clinical records and then assessed its performance directly with patients. The findings were as follows: neurologists agreed with the AI's decisions nearly all the time, and the AI outperformed earlier versions of Chat GPT in every tested aspect. Patients and doctors found the AI to be highly effective, rating it as excellent or very good in most cases. This suggests the AI could significantly enhance how quickly and accurately neurological emergencies are dealt with, although further trials are needed before it can be widely used. conditions: Stroke conditions: Guillain-Barre Syndrome conditions: Facial Palsy conditions: Migraine conditions: Status Epilepticus conditions: Vertigo Benign Positional conditions: Delirium conditions: Trigeminal Neuralgia conditions: Meningitis conditions: Subarachnoid Hemorrhage studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: The model of this Phase 1 interventional study involves evaluating the diagnostic accuracy and utility of an AI-powered virtual assistant in the triage of emergency neurological conditions. Patients and healthcare professionals interacted with the assistant, providing real-world clinical scenarios to assess its effectiveness. The study's design aimed to demonstrate the assistant's potential to enhance emergency neurological care by comparing its performance with established diagnostic tools and patient outcomes. primaryPurpose: DIAGNOSTIC masking: NONE count: 10 type: ACTUAL name: Virtual Assistant measure: Diagnostic performance measure: Appropriate medical conduct or recommendation measure: Assessment of Usability and Satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fleni city: Buenos Aires zip: 1428 country: Argentina lat: -34.61315 lon: -58.37723 hasResults: False
nctId: NCT06334783 id: HV-IIT briefTitle: TIL for Patients With Advanced Solid Tumor overallStatus: RECRUITING date: 2023-05-30 date: 2025-12-31 date: 2026-12-31 date: 2024-03-28 date: 2024-03-28 name: Hervor Therapeutics class: INDUSTRY name: Jinling Hospital, China name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences name: Women's Hospital School Of Medicine Zhejiang University briefSummary: Background:
4. At last TIL cells will be re-infused into the patients. conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Autologous tumor-infiltrating lymphocyte cells measure: Safety of TIL measure: Overall Response Rate (ORR) measure: Duration of Response (DOR) measure: Disease Control Rate (DCR) measure: Progression free survival (PFS) measure: Overall survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center status: RECRUITING city: Shenzhen state: Guangdong country: China name: Xiugui Sheng, PhD role: CONTACT email: hanxiuchen@yeah.net lat: 22.54554 lon: 114.0683 facility: Nanjing Jinling Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210000 country: China name: Tangfeng Lv, PhD role: CONTACT phone: +86 25 8086 0114 email: bairoushui@163.com lat: 32.06167 lon: 118.77778 facility: Wowen's hospital, School of medicine, Zhejiang University status: NOT_YET_RECRUITING city: Hangzhou state: Zhejiang country: China name: Hui Wang, PhD role: CONTACT email: 5198008@zju.edu.cn lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06334770 id: FDASuRecD032136 briefTitle: Influence of Roxolid Implant Material on the Implant Stability Implant Stability acronym: BLX overallStatus: COMPLETED date: 2021-06-15 date: 2022-01-22 date: 2023-12-12 date: 2024-03-28 date: 2024-03-28 name: Ain Shams University class: OTHER briefSummary: Fourteen completely edentulous patients were selected to participate in this study. From the outpatient clinic of Prosthodontic Department, Faculty of Dentistry, Ain Shams University.
Patients were recalled frequently for post-insertion inspection and adjustment. conditions: Completely Edentulous Patients studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 18 type: ACTUAL name: Roxolid implants name: Titanium implants measure: measuring primary at time of surgery measure: secondary implant stability after 6 weeks sex: ALL minimumAge: 45 Years maximumAge: 60 Years stdAges: ADULT facility: Faculty of Dentistry of Dentistry Ainshams Univeristy city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06334757 id: HLX10IIT22 briefTitle: Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure overallStatus: RECRUITING date: 2023-05-08 date: 2024-08-31 date: 2025-06-30 date: 2024-03-28 date: 2024-03-28 name: Henan Cancer Hospital class: OTHER_GOV briefSummary: The purpose of this study is to evaluate the efficacy and safety of Serplulimab Plus Bevacizumab and chemotherapy in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients. conditions: Non-Squamous Non-Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 46 type: ESTIMATED name: Serplulimab name: Bevacizumab Biosimilar HLX04 name: Pemetrexed name: Carboplatin measure: ORR(Overall Response Rate) measure: PFS(Progression Free Survival) measure: OS(Overall Survival) measure: AE(Adverse Event) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Henan Cancer Hospital status: RECRUITING city: Zhengzhou state: Henan zip: 450003 country: China name: zhen he role: CONTACT phone: 13523530961 lat: 34.75778 lon: 113.64861 hasResults: False
nctId: NCT06334744 id: COVAR briefTitle: Ambispective Observational Multicenter Study on the Efficacy of the Third Dose of Vaccine Anti COVID-19 in Patients Suffering From Solid Tumors Undergoing Oncological Treatment Active. overallStatus: COMPLETED date: 2021-11-17 date: 2023-01-08 date: 2023-06-08 date: 2024-03-28 date: 2024-03-29 name: Fondazione IRCCS Policlinico San Matteo di Pavia class: OTHER briefSummary: To evaluate the serum neutralizing antibody titre in cancer patients undergoing active treatment against variants (VOC) before and after the third dose of BNT162b2 COVID-19 vaccine. conditions: Oncologic Complications studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ACTUAL measure: Determination of the change in neutralizing antibodies against SARS-CoV-2 (CLIA method) towards VOCs before the third dose of COVID-19 vaccine and 21 days after the same. measure: Evaluation of the kinetics of neutralizing antibodies and anti-SARS-CoV-2 IgG titer (CLIA method) up to 52 weeks after the third dose of COVID-19 vaccine measure: Evaluation of the incidence of virologically confirmed cases of VOC after administration of the third dose of vaccine. measure: Evaluation of the incidence of local and systemic adverse reactions (ARs), directly or indirectly linked to the vaccine, in an observation period up to 4 weeks later the third dose of vaccine. measure: Evaluation of the incidence of "New onset" immune-related adverse events (IRAEs), such as immune-related pruritus, rashes, hypophysitis, hepatitis, pneumonia, diarrhoea, colitis in patients undergoing immunotherapy. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Irccs San Matteo Pavia city: Pavia state: PV zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06334731 id: 045.PHA.2021.D briefTitle: Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic overallStatus: RECRUITING date: 2021-07-06 date: 2024-12 date: 2024-12 date: 2024-03-28 date: 2024-03-28 name: Methodist Health System class: OTHER briefSummary: Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic. conditions: COVID-19 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED measure: Incidence of third generation cephalosporin-resistant bacteria (3GCRB) measure: Incidence of ESBLPE measure: Incidence of CRB measure: Incidence of other pathogens measure: Incidence of nosocomial infections measure: Incidence of clinical outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Methodist Dallas Medical Center status: RECRUITING city: Dallas state: Texas zip: 75203 country: United States name: Matthew Crotty, PharmD role: CONTACT phone: 214-941-2400 email: matthewcrotty@mhd.com name: Matthew Crotty, PharmD role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06334718 id: 318417 id: NIHR204382 type: OTHER_GRANT domain: National Institute for Health and Care Research briefTitle: Drone Delivered Defibrillators (The 3D Project). overallStatus: RECRUITING date: 2024-03-29 date: 2024-08-22 date: 2024-10-31 date: 2024-03-28 date: 2024-04-09 name: University of Warwick class: OTHER name: Welsh Ambulance Service NHS Trust briefSummary: The goal of this observational study is to explore the optimisation and integration of a drone-delivered Automated External Defibrillator (AED) system into the pre-hospital response to out-of-hospital cardiac arrest. The study is being conducted by the University of Warwick and Welsh Ambulance Service National Health Service Trust (both in the UK)
In work package 2 the investigators will conduct simulated cardiac arrests. The participants in the study will make an emergency (999) call to a trained call-handler and, once the cardiac arrest is identified during the call, a drone will be activated from a distant location and fly up to 2km to the test site and deliver an AED. The investigators will record how long it takes to retrieve and attach the AED, and ask the participants for their views about the interaction with the call-handler, AED and drone. conditions: Cardiac Arrest, Out-Of-Hospital studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 44 type: ESTIMATED name: Interviews and simulation measure: Time away from patient's side (SIMULATION) measure: Barriers and facilitators to drone-delivered AED use (INTERVIEW) measure: Interventions to overcome barriers to drone delivered AED use (INTERVIEW) measure: Hands off CPR time (SIMULATION) measure: Total time from start of 999 call to AED application and first shock (SIMULATION) measure: Total drone flight time (SIMULATION) measure: Time from drone arrival to safe to approach (SIMULATION) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Warwick status: RECRUITING city: Coventry country: United Kingdom name: Christopher M Smith, MBChB, PhD role: CONTACT phone: (+44)2476151083 lat: 52.40656 lon: -1.51217 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-02-27 uploadDate: 2024-03-11T10:47 filename: Prot_000.pdf size: 1072430 hasResults: False
nctId: NCT06334705 id: C22-11 id: 2022-A02312- 41 type: REGISTRY domain: IDRCB briefTitle: EGEA4 THE 30 YEAR FOLLOW UP OF THE EGEA STUDY overallStatus: RECRUITING date: 2024-02-15 date: 2027-02-15 date: 2028-02-15 date: 2024-03-28 date: 2024-03-28 name: Institut National de la Santé Et de la Recherche Médicale, France class: OTHER_GOV name: APHP name: CHU LYON name: APHM name: University Hospital, Grenoble name: University Hospital, Montpellier briefSummary: Cardiovascular (CV) diseases affect 523 million people worldwide, and are the leading cause of death, accounting for over 18 million deaths (around 30% of all deaths) every year. CV diseases account for around 45% of all deaths in Europe, or around 140,000 deaths a year in France. Asthma is one of the main non-communicable diseases, with a significant societal and individual burden, particularly in subjects suffering from severe asthma. The prevalence of asthma worldwide has risen rapidly over the past five decades, and now affects 272 million people worldwide, representing a prevalence of around 3.6%.
We hypothesize that asthma, and more specifically adult and moderate-to-severe asthma, are associated with early markers of CV risk. Furthermore, by providing a better understanding of the mechanisms involved in this association, we hypothesize that EGEA_30years may help to disentangle and prioritize actionable levers of life-threatening cardiovascular comorbidities in asthma. conditions: Healthy Volunteer EGEA4 Cohort studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 1000 type: ESTIMATED name: blood test, food collection, hair collection, calcium scan, etc. measure: Framingham score variability between asthmatics and non-asthmatics measure: Aortic pulse wave velocity measure: validated predictive biomarkers of CV disease (NTproBNP, Troponin(I) hs), measure: Soluble ST2 measure: coronary calcium score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hospitalier Universitaire Grenoble Alpes status: RECRUITING city: Grenoble zip: 38043 country: France name: Bruno DEGANO, PhD role: CONTACT email: BDEGANO@chu-grenoble.fr lat: 45.16667 lon: 5.71667 facility: Hopital de la Croix Rousse status: RECRUITING city: Lyon zip: 69317 country: France name: Gilles Mr DEVOUASSOUX, MD role: CONTACT email: gilles.devouassoux@chu-lyon.fr lat: 45.74848 lon: 4.84669 facility: APHM status: RECRUITING city: Marseille zip: 13000 country: France name: Pascal CHANEZ, PhD role: CONTACT email: pascal.chanez@univ-amu.fr lat: 43.29551 lon: 5.38958 facility: Hôpital Arnaud De Villeneuve status: RECRUITING city: Montpellier zip: 34295 country: France name: Pascal Mr DEMOLY, PHD role: CONTACT email: pascal.demoly@inserm.fr lat: 43.61092 lon: 3.87723 facility: APHP - Hôpital Bichat Claude Bernard status: RECRUITING city: Paris zip: 75018 country: France name: Camille TAILLE, PHD role: CONTACT email: camille.taille@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06334692 id: BLINDER briefTitle: Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome acronym: BLINDER overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-05 date: 2028-05 date: 2024-03-28 date: 2024-04-11 name: Mario Negri Institute for Pharmacological Research class: OTHER briefSummary: This retrospective study is aimed at evaluating the levels of circulating anti-nephrin autoantibodies in patients with INS, including those with MCD/FSGS and in patients who have experienced relapse of FSGS post-transplant, compared to those of a control group of patients with nephrotic syndrome due to primary membranous nephropathy (MN). conditions: Nephrotic Syndrome studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED name: In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa). measure: Levels of circulating anti-nephrin autoantibodies sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Research Center for Rare Disease Aldo e Cele Daccò city: Ranica state: BG zip: 24020 country: Italy name: Federica Casiraghi, PhD role: CONTACT phone: +3903545351 email: federica.casiraghi@marionegri.it lat: 45.72328 lon: 9.71335 hasResults: False